Literature DB >> 21971734

Corticosteroid-use in primary and secondary brain tumour patients: a review.

Richella Ryan1, Sara Booth, Stephen Price.   

Abstract

Corticosteroids have been effective in the management of cerebral oedema, in the context of brain tumours, for many decades. Though their effectiveness is well-established, this needs to be balanced against their potential to cause significant side effects. There is currently little consensus in the literature about how this should be done. This article reviews the literature, specifically in relation to the role of corticosteroids in primary and secondary brain tumour patients. Areas reviewed include corticosteroid pharmacology, indications, mechanism of action, toxicity profile, prescribing practices, and corticosteroid-sparing agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21971734     DOI: 10.1007/s11060-011-0713-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  64 in total

Review 1.  Corticosteroid-induced osteoporosis: pathogenesis and prevention.

Authors:  S Benvenuti; M L Brandi
Journal:  Clin Exp Rheumatol       Date:  2000 Jul-Aug       Impact factor: 4.473

2.  Aquaporin-4 expression is increased in oedematous human brain tumours.

Authors:  S Saadoun; M C Papadopoulos; D C Davies; S Krishna; B A Bell
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

3.  Steroid requirements during radiotherapy for malignant gliomas.

Authors:  Athina Marantidou; Christine Levy; Alyette Duquesne; Renata Ursu; Olivier Bailon; Irene Coman; Catherine Belin; Antoine F Carpentier
Journal:  J Neurooncol       Date:  2010-02-26       Impact factor: 4.130

Review 4.  Corticosteroid-Induced osteoporosis: detection and management.

Authors:  J D Adachi; A Papaioannou
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme.

Authors:  S Liebner; A Fischmann; G Rascher; F Duffner; E H Grote; H Kalbacher; H Wolburg
Journal:  Acta Neuropathol       Date:  2000-09       Impact factor: 17.088

6.  Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study.

Authors:  B Badie; J M Schartner; J Paul; B A Bartley; J Vorpahl; J K Preston
Journal:  J Neurosurg       Date:  2000-10       Impact factor: 5.115

7.  Defining the impact and contribution of steroids in patients receiving whole-brain irradiation for cerebral metastases.

Authors:  B M Millar; A Bezjak; M Tsao; A Sturdza; N Laperriere
Journal:  Clin Oncol (R Coll Radiol)       Date:  2004-08       Impact factor: 4.126

8.  Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank Attenello; Khoi Than; Amado Jimenez Ruiz; Alessandro Olivi; Alfredo Quiñones-Hinojosa
Journal:  Neurosurgery       Date:  2008-08       Impact factor: 4.654

9.  Corticosteroid toxicity in neuro-oncology patients.

Authors:  D E Weissman; D Dufer; V Vogel; M D Abeloff
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

Review 10.  The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Timothy C Ryken; Michael McDermott; Paula D Robinson; Mario Ammirati; David W Andrews; Anthony L Asher; Stuart H Burri; Charles S Cobbs; Laurie E Gaspar; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-03       Impact factor: 4.130

View more
  17 in total

1.  Validating self-report and proxy reports of the Dexamethasone Symptom Questionnaire -Chronic for the evaluation of longer-term corticosteroid toxicity.

Authors:  Meera Agar; Eng-Siew Koh; Emma Gibbs; Elizabeth H Barnes; Elizabeth Hovey; Ann Livingstone; Kate Sawkins; Richard Chye; Melanie R Lovell; Katherine Clark; Janette Vardy; Madeleine King
Journal:  Support Care Cancer       Date:  2015-08-21       Impact factor: 3.603

2.  Provider views on perioperative steroid use for patients with newly diagnosed pediatric brain tumors.

Authors:  Fatema Malbari; Kristen A Staggers; Charles G Minard; Howard L Weiner; Murali M Chintagumpala; Adam S Levy
Journal:  J Neurooncol       Date:  2020-02-05       Impact factor: 4.130

Review 3.  Managing Disease and Therapy-Related Complications in Patients with Central Nervous System Tumors.

Authors:  Jeffrey J Raizer; Karan S Dixit
Journal:  Curr Treat Options Oncol       Date:  2015-08

Review 4.  Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.

Authors:  Terri S Armstrong; Allison M Bishof; Paul D Brown; Martin Klein; Martin J B Taphoorn; Christina Theodore-Oklota
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

5.  The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic.

Authors:  Terri S Armstrong; Yuan Ying; Jimin Wu; Alvina A Acquaye; Elizabeth Vera-Bolanos; Mark R Gilbert; Paul D Brown; Janette Vardy; Caroline Chung
Journal:  Neuro Oncol       Date:  2015-04-09       Impact factor: 12.300

Review 6.  Medical management of brain tumors and the sequelae of treatment.

Authors:  David Schiff; Eudocia Q Lee; Lakshmi Nayak; Andrew D Norden; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2014-10-30       Impact factor: 12.300

Review 7.  End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review.

Authors:  Tobias Walbert; Muhib Khan
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

Review 8.  Neurocognitive function after radiotherapy for paediatric brain tumours.

Authors:  Laetitia Padovani; Nicolas André; Louis S Constine; Xavier Muracciole
Journal:  Nat Rev Neurol       Date:  2012-09-11       Impact factor: 42.937

9.  Steroid management in newly diagnosed glioblastoma.

Authors:  Mariel B Deutsch; Katherine S Panageas; Andrew B Lassman; Lisa M Deangelis
Journal:  J Neurooncol       Date:  2013-03-06       Impact factor: 4.130

Review 10.  Neuroinflammation: A Signature or a Cause of Epilepsy?

Authors:  Enrico Pracucci; Vinoshene Pillai; Didi Lamers; Riccardo Parra; Silvia Landi
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.